Drug intelligence / Profile preview

PBSA02

Development stage: Preclinical
Lead developer: Hankuk University of Foreign Studies
Administration: Inhalation, Intravenous, Topical

Overview

PBSA02 is a lytic bacteriophage targeting *Staphylococcus aureus*, including methicillin-resistant *Staphylococcus aureus* (MRSA). Sourced from the Korean Phage Biobank, PBSA02 has demonstrated broad lytic activity against various MRSA sequence types (STs), particularly ST93 and ST30. It has been evaluated in clinical trials and compassionate use programs, such as the Standardised Treatment and Monitoring Protocol (STAMP) study in Australia, for the treatment of severe MRSA infections, including necrotising pneumonia.

Other names: bacteriophage PBSA02phage PBSA02

Beyond the preview

Go deeper on PBSA02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBSA02.